Johnson & Johnson's Q2 2019 earnings show continued growth despite generic competition and some price pressures.  Management highlights strong performance in key products like DARZALEX, IMBRUVICA and STELARA, and accelerating growth in Consumer Health.  The company is increasing their investment in R&D and acquiring new businesses (Auris Health), suggesting confidence in longer-term opportunities, and projecting a slight increase in operational sales growth for the rest of the year.
2
